Vastned NV
Vastned on track after the first quarter of 2025
Vastned on track after the first quarter of 2025
• Fair value of real estate portfolio increases by € 15.4 million (+ 1.2% compared to 31 December 2024 - pro forma).
• EPRA earnings of € 0.48 per share for the first quarter of 2025.
• The occupancy rate remains at a high level of 98.5%.
• The debt ratio (EPRA LTV) is 41.97%, compared to 43.04% at 31 December 2024 (pro forma). Vastned is confident that the target EPRA LTV of 40% can be achieved by the end of this year.
• In April 2025, Vastned obtained a binding offer to refinance the € 50.0 million credit facility – which matures in September 2025.
• Forward starting Interest Rate Swaps were concluded for a notional amount of € 95.0 million. These IRS contracts will go into effect in September 2025 and replace the expiring IRS contracts with a notional amount of € 150.0 million. As a result of the conclusion of these forward starting IRS contracts, the expected average interest rate for 2026 decreases to 3.8% as compared to the previously communicated 3.9%.
• Vastned is on track to achieve its objectives and confirms its expected EPRA earnings per share between € 1.95 and € 2.05.
• On 24 March 2025, Vastned joined the BEL Mid Index with a market capitalization of over € 500.0 million.
Full press release:
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Jeito Capital13.5.2025 07:05:00 CEST | Press release
Jeito Capital leads EUR 132 million oversubscribed Series B financing in Azafaros to advance Phase 3 clinical programs of innovative therapies in rare inherited neuro-metabolic disorders
Vivoryon Therapeutics N.V.13.5.2025 07:00:00 CEST | Press release
Vivoryon Therapeutics N.V. to Hold its 2025 Annual General Meeting on June 24, 2025
Kuros Biosciences AG13.5.2025 07:00:00 CEST | Press release
Kuros Biosciences to share latest MagnetOs™ market impact and strategic priorities at Capital Market Day in Zürich
dsm-firmenich13.5.2025 07:00:00 CEST | Press release
Weekly progress on share repurchase program to cover share plans and reduce capital
NMD Pharma13.5.2025 07:00:00 CEST | Press release
NMD Pharma to present compelling preclinical data highlighting the potential of ClC-1 ion channel inhibition to improve disease symptoms and progression in MuSK myasthenia gravis at the MGFA International Conference on Myasthenia and Relate
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom